Novartis23h
Oferty pracy
Stanowisko Sortuj rosnąco Biznes Położenie Witryna Data publikacji Territory Business Executive Regular (Sales), Full time Innovative Medicines India Telangana Lut 12, 2025 Territory Business ...
Novartis1d
Career Search
Job Title Sort ascending Business Location Site Date Posted Consultor Técnico Especialidades Sênior Regular (Vendas), Full time Innovative Medicines Brazil Santo Amaro Feb 05, 2025 MSL, Temporary ...
Novartis2d
Offene Stellen
(高级）医药代表 /（资深）产品专员 Redni sodelavec (prodaja), Full time Innovative Medicines China Xi an (Shaanxi Province) Feb 13, 2025 ...
Novartis2d
Buscar vagas
(高级）医药代表 /（资深）产品专员 Redni sodelavec (prodaja), Full time Innovative Medicines China Xi an (Shaanxi Province) fev 13, 2025 ...
Novartis4d
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...
Novartis4d
Offene Stellen
Vodja nabave materialov za lokacije (m/ž/d) / Site External Material Lead (m/f/d) Temporary (Fixed Term), Full time Innovative Medicines Slowenien Mengeš Feb 11, 2025 ...
Novartis6d
Zaposlitev v Novartisu v Sloveniji
V Novartisu spodbujamo inovativnost in razvoj ter delujemo na številnih področjih. Tudi vi lahko postanete del tega, del naše zgodbe. Pridružite se naši ustvarjalni skupnosti strokovnjakov in našli ...
Novartis11d
Višji poslovni partner za pridobivanje talentov in zaposlovanje (m/ž/d) / Senior TAS Business Partner (m/f/d)
Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each ...
Novartis12d
Field Medical Lead (Renal)
Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each ...
Novartis15d
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 47 of the Condensed Financial Report. Unless otherwise ...
Novartis15d
Novartis setzt die starke Umsatzdynamik mit Margenerhöhungen fort und erreicht 2024 wichtige Meilensteine bei Innovationen
1. Die Angaben in konstanten Wechselkursen (kWk), die Kernergebnisse und der Free Cashflow sind Nicht-IFRS-Kennzahlen. Erläuterungen der Nicht-IFRS-Kennzahlen finden sich auf Seite 47 der in ...
Novartis17d
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...